Table 1.
Baseline characteristics by bebtelovimab treatment status for primary matched cohort.
| Bebtelovimab (n = 3739) |
Untreated (n = 5423) |
|
|---|---|---|
| Age groupa | ||
| 18-44 years | 877 (23.5%) | 1643 (30.3%) |
| 45-64 years | 1160 (31.0%) | 1795 (33.1%) |
| ≥65 years | 1702 (45.5%) | 1985 (36.6%) |
| Female sex | 2196 (58.7%) | 3221 (59.4%) |
| Race/Ethnicity | ||
| Non-Hispanic White | 3200 (85.6%) | 4566 (84.2%) |
| Hispanic | 289 (7.7%) | 486 (9.0%) |
| Non-Hispanic Black | 101 (2.7%) | 138 (2.5%) |
| Other | 149 (4.0%) | 233 (4.3%) |
| Insurance statusa | ||
| Private/Commercial | 1834 (49.1%) | 3193 (58.9%) |
| Medicare | 1728 (46.2%) | 1920 (35.4%) |
| Medicaid | 113 (3.0%) | 196 (3.6%) |
| Other (None/Uninsured/Unknown) | 64 (1.7%) | 114 (2.1%) |
| Immunocompromiseda | ||
| Mild | 515 (13.8%) | 610 (11.2%) |
| Moderate/severe | 711 (19.0%) | 748 (13.8%) |
| Obesea | 1052 (28.1%) | 1301 (24.0%) |
| Number of other comorbid conditions | ||
| One | 1005 (26.9%) | 1644 (30.3%) |
| Two or more | 1652 (44.2%) | 1840 (33.9%) |
| Diabetes mellitus | 737 (19.7%) | 788 (14.5%) |
| Cardiovascular disease | 987 (26.4%) | 1088 (20.1%) |
| Pulmonary disease | 1233 (33.0%) | 1514 (27.9%) |
| Renal disease | 581 (15.5%) | 482 (8.9%) |
| Hypertension | 1785 (47.7%) | 2,234 (41.2%) |
| Liver disease | ||
| Mild | 455 (12.2%) | 488 (9.0%) |
| Severe | 66 (1.8%) | 33 (0.6%) |
| Number of vaccinations prior to SARS-CoV-2+ datea | ||
| 0 | 578 (15.5%) | 955 (17.6%) |
| 1 | 128 (3.4%) | 204 (3.8%) |
| 2 | 479 (12.8%) | 708 (13.1%) |
| 3+ | 2554 (68.3%) | 3556 (65.6%) |
a
Variables used in the propensity matching, along with cohort week (not listed).